Keros Therapeutics Inc 뉴스 - KROS | 주식 나스닥 | ADVFN

다우존스 지수

브라질 증권 거래소, NASDAQ, NYSE, AMEX, LSE 등 주요 거래소에서의 다양한 실시간 주식 시세를 모니터링합니다.

등록

홈
인베스팅
주식
미국
NASDAQ
Keros Therapeutics Inc (KROS)
Keros Therapeutics Inc (KROS) 뉴스

Keros Therapeutics Inc (KROS)

10.915

-0.465

(-4.09%)

마감 11 3월 5:00AM

10.76

-0.155

(-1.42%)

시간외 거래: 8:31AM

개인 투자자를 위한 전문가급 도구.

Form 8-K - Current report

Form 8-K - Current report

Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences

LEXINGTON, Mass., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a...

Form S-8 - Securities to be offered to employees in employee benefit plans

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Form 8-K - Current report

Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results

LEXINGTON, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Keros Therapeutics to Present at the Guggenheim SMID Cap Biotech Conference

LEXINGTON, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a...

Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]

Form 8-K - Current report

Keros Therapeutics Announces Effectiveness of Global License Agreement with Takeda to Advance Elritercept

LEXINGTON, Mass., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”...

TheFinalCD

TheFinalCD 2 월 전

$KROS halts all dosing in the TROPOS Phase 2 clinical trial of cibotercept (KER-012) based on the ongoing safety review due to new observations of pericardial effusion adverse events

$KROS halts all dosing in the TROPOS Phase 2 clinical trial of cibotercept (KER-012) based on the ongoing safety review due to new observations of pericardial effusion adverse events— Bio Stocks™ (@BioStocks) January 15, 2025

$KROS the TROPOS trial is being terminated early. The Co continues to expect to present topline data from all treatment arms in this trial in Q2
$KROS the TROPOS trial is being terminated early. The Co continues to expect to present topline data from all treatment arms in this trial in Q2— Bio Stocks™ (@BioStocks) January 15, 2025

retireat40

retireat40 3 월 전

Wow. What a turd

retireat40

retireat40 3 월 전

Shocked this is still sub 18

Dennis14

Dennis14 3 월 전

Bought in at 18.00

Monksdream

Monksdream 6 월 전

KROS more upside possible

Monksdream

Monksdream 1 년 전

KROS new 52=week high

Keros Therapeutics

Delayed Upgrade Clock

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관